SRBAs exert a chelating action that effectively terminates an NMBA ability to bind to nicotinic receptors.
Sugammadex is a modified gamma cyclodextrin that specifically encapsulates and binds the aminosteroid NMBAs: affinity is highest for rocuronium, followed by vecuronium, and relatively low affinity for pancuronium.
Early research suggests it may have a lower incidence of adverse reactions than sugammadex [2][3] 3.
[5] The discovery of SRBA as a new class of drug is the result of work done by Organon laboratories at the Newhouse research site in Scotland.
Cyclodextrins were explored as a means to solubilize rocuronium bromide (a steroidal NMBA) in a neutral aqueous solution.